View in EDS HTML Full Text PDF Full Text

Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.

Saved in:
Bibliographic Details
Title: Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
Authors: Diamantopoulos, Panagiotis T.1 (AUTHOR) pandiamantopoulos@gmail.com, Kontandreopoulou, Christina-Nefeli1 (AUTHOR), Stafylidis, Christos1 (AUTHOR), Vlachopoulou, Dimitra1 (AUTHOR), Giannakopoulou, Nefeli1 (AUTHOR), Vardaka, Maria2 (AUTHOR), Mpouhla, Anthi3 (AUTHOR), Variami, Eleni1 (AUTHOR), Galanopoulos, Athanasios2 (AUTHOR), Pappa, Vassiliki3 (AUTHOR), Psichogiou, Mina1 (AUTHOR), Hatzakis, Angelos4 (AUTHOR), Viniou, Nora-Athina1 (AUTHOR)
Source: Annals of Hematology. Dec2022, Vol. 101 Issue 12, p2711-2717. 7p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:09395555
DOI:10.1007/s00277-022-05003-6